行情

BPMC

BPMC

蓝图医药
NASDAQ

实时行情|Nasdaq Last Sale

78.48
+3.92
+5.26%
盘后: 78.48 0 0.00% 16:08 12/06 EST
开盘
74.84
昨收
74.56
最高
78.71
最低
74.07
成交量
43.55万
成交额
--
52周最高
102.98
52周最低
44.58
市值
38.61亿
市盈率(TTM)
-10.0927
分时
5日
1月
3月
1年
5年

分析师评级

14位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

BPMC 新闻

  • Hedge Funds Love Medicines Corporation (BPMC) Way More Than These Stocks
  • Insider Monkey.8小时前
  • Why Is Blueprint Medicines (BPMC) Up 1.4% Since Last Earnings Report?
  • Zacks.1天前
  • 意大利最大商业银行拟裁员8000人
  • 新浪财经.3天前
  • 意大利总理支持欧洲稳定机制改革 遭反对党批评
  • 中国新闻网.3天前

更多

所属板块

生物技术和医学研究
+1.28%
制药与医学研究
+0.68%

热门股票

名称
价格
涨跌幅

BPMC 简况

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.
展开

Webull提供Blueprint Medicines Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。